{
  "id": 16982264,
  "title": "Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma",
  "url": "https://urgent.news/2026/10/29/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T00:29:12.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-of-toripalimab-subsutaneous-injection-for-the-1st-line-treatment-of-her2-expressing-urothelial-carcinoma"
  },
  "original_language": "en",
  "account": null,
  "summary": "SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for the company’s product, toripalimab injection (subcutaneous injection)…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}